deltatrials
Completed PHASE3 INTERVENTIONAL 16-arm NCT03334435

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3)

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

Sponsor: Eli Lilly and Company

Conditions Atopic Dermatitis
Interventions Baricitinib Placebo
Updated 39 times since 2017 Last updated: Aug 30, 2024 Started: Mar 28, 2018 Primary completion: Sep 21, 2020 Completion: Jul 12, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atopic Dermatitis, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 39 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Dec 2021 · 7 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Dec 2025 · 2 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

39 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Oct 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  4. Oct 2024 — Sep 2025 [monthly]

    Completed PHASE3

  5. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE3

▶ Show 34 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  2. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. May 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  7. May 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  9. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  10. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  11. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  12. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

  13. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  14. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  15. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  16. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  17. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  18. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  19. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  20. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  21. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  22. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  23. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  24. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  25. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  26. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  27. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  28. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  29. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  30. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  31. Mar 2018 — May 2018 [monthly]

    Not Yet Recruiting PHASE3

  32. Feb 2018 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE3

  33. Jan 2018 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE3

  34. Dec 2017 — Jan 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
  • Incyte Corporation
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aarhus, Denmark , Adelaide, Australia , Afula, Israel , Ahmedabad, India , Ainokawa, Ichikawa-shi, Japan , Alicante, Spain , Ansan-si, South Korea , Barcelona, Spain , Benowa, Australia and 140 more locations